GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exelixis Inc (FRA:EX9) » Definitions » Float Percentage Of Total Shares Outstanding

Exelixis (FRA:EX9) Float Percentage Of Total Shares Outstanding : 74.83% (As of Jun. 07, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Exelixis Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Exelixis's float shares is 217.97 Mil. Exelixis's total shares outstanding is 291.29 Mil. Exelixis's float percentage of total shares outstanding is 74.83%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Exelixis's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Exelixis's Institutional Ownership is 54.14%.

Exelixis Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Exelixis's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=217.97/291.29
=74.83%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Exelixis (FRA:EX9) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exelixis Inc (FRA:EX9) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
RVMD HALO BPMC IONS JAZZ BBIO VKTX CYTK APLS MDGL OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
EXEL:USA EX9:Germany
Address
1851 Harbor Bay Parkway, Alameda, CA, USA, 94502
Website
https://www.exelixis.com
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Exelixis (FRA:EX9) Headlines

No Headlines